• Ep. 11: Impatient, with Tempus/Groupon’s Eric Lefkofsky
  • Prev
  • Next
“Today, if somebody’s positive for COVID-19, it still doesn't tell you what's likely to happen next. And what we're trying to do by combining clinical and molecular data is really be able to predict what's likely to happen to them next.”

When Groupon founder Eric Lefkofsky’s wife was diagnosed with cancer, he found the lack of data maddening. Outside of her hospital it was the 21st century, but once he passed through the doors he felt he was being ushered two or three decades into the past.

He launched Tempus to change that. The company analyzes vast pools of genetic data to find and develop therapeutics for conditions ranging from cancers to major depressive disorder. He’s especially frustrated at the lack of progress in the current crisis. “We now have in this country over 400,000 patients who have tested positive for COVID-19,” he tells Mike. “Where is that data? Why don’t we have that data in one central place?”

For Lefkofsky, the promise of personalized medicine means finding and developing the right medicine for the right patient at the right time. Today, any of us may be the next patient, and the clock is ticking.

Share


Eric Lefkofsky

Founder and CEO, Tempus


View